Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 15Dermatologic 12Thoracic 8Other hematologic neoplasm 4Breast 4Head & Neck 2Sarcoma 1Plasma cell 1Myeloid 1Gastrointestinal 1Classical hematology 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Bexarotene × Breast × Clear all
NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

National Cancer Centre, Singapore

Phase 1 Completed
12 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03323658 2023-01-10

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled 12 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT00003752 2013-05-30

Bexarotene in Treating Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
180 enrolled
Breast

Breast Neoplasms

NCT00055991 2013-02-05

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

Baylor Breast Care Center

Phase 1 Completed
87 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡